GET DAILY SIGNALSWhy Is Eli Lilly and Company (LLY) Stock Up +0.64% Today?
Key Takeaways
- LLY shares were up roughly 0.64% in Monday's session, holding near $1,420 as the post-earnings rally extended into record territory.
- The primary catalyst is continued follow-through buying after blowout third-quarter results, with revenue up 39% year over year to $24.4 billion.
- Secondary drivers include a fresh round of analyst price-target increases and sustained momentum in the GLP-1 obesity franchise led by Mounjaro and Zepbound.
- Broader context: health-care and weight-loss drug names have outperformed as investors rotate away from richly valued technology stocks.
- What traders are watching next: the company's December 7 investment community meeting and the planned retatrutide regulatory submission.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages on Tickeron.
- Discover actionable trading ideas by exploring Trending AI Robots.
Opening Summary
Eli Lilly and Company (LLY), the Indianapolis-based pharmaceutical giant best known for its diabetes and obesity medicines, extended its upward run on Monday. The stock was trading near $1,420.09, up about 0.64% from its previous session close of $1,410.99. The modest gain reflects continued bullish sentiment following last week's stronger-than-expected third-quarter earnings report, which sent shares to an all-time high and pushed the company's market value above $1.3 trillion.
Earnings-Driven Momentum Carries Over
The dominant force behind the move is the company's third-quarter report, released on October 29. Revenue surged 39% year over year to $24.4 billion, comfortably ahead of consensus estimates, while adjusted earnings per share rose 7% to $7.48. Mounjaro, the company's diabetes therapy, posted worldwide sales of roughly $10.7 billion, up 65%, while the obesity treatment Zepbound climbed 49% to about $5.35 billion. Together, the two GLP-1 products accounted for roughly two-thirds of total revenue.
Raised Guidance Reinforces the Bull Case
Management lifted its full-year revenue outlook to a range of $91 billion to $92 billion, up from a prior $85 billion to $87 billion, marking the third increase this year. The upgrade signaled that supply and demand for the company's incretin franchise remain robust, even as realized prices declined. Analysts responded quickly, with several firms raising their targets, including Morgan Stanley to $1,596, JPMorgan to $1,650, and UBS to $1,625, reinforcing the market's upbeat reaction.
Obesity Pipeline and Access Expansion
Investors are also pricing in a deeper pipeline. The oral obesity therapy Foundayo, launched in the U.S. in April 2026, is being evaluated in additional indications and international markets, while the next-generation candidate retatrutide is expected to be submitted for U.S. regulatory approval in the first quarter of 2027. Separately, the Medicare GLP-1 Bridge program has expanded access, with more than 500,000 patients accessing Lilly's obesity medicines, the majority of them new to incretin treatment.
Market Context and Trading Activity
The move aligned with broader rotation into health care and weight-loss drug names, which have outperformed as investors diversify away from technology stocks. The stock's advance has been persistent rather than explosive in Monday's session, consistent with consolidation near record highs rather than a fresh catalyst-driven breakout. LLY remains well above its prior 52-week high near $1,321 and trades at a significant premium to large-cap pharmaceutical peers, reflecting the market's expectation that its GLP-1 growth story will continue.
What Comes Next for LLY
Looking ahead, investors will focus on the December 7 investment community meeting, where management is expected to outline its drug pipeline and long-term growth strategy. Additional catalysts include retatrutide clinical data and regulatory developments, international launches of Foundayo, and continued expansion of manufacturing capacity. Key risks include pricing pressure on GLP-1 therapies, intensifying competition from rivals such as Novo Nordisk, and an elevated valuation that leaves little room for disappointment. Any slowdown in incretin demand or a pipeline setback could quickly pressure the shares.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots, chosen from hundreds of available strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a way to explore data-driven approaches. Visit the page to see which automated strategies are gaining momentum right now.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LLY in upward trend: 10-day moving average broke above 50-day moving average on October 15, 2026
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 51 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 37 of 44 cases over the following month. The odds of a continued upward trend are 84%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 231 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (37.123) is slightly higher than the industry average of (-1.476). P/E Ratio (47.269) is within average values for comparable stocks, (21.871). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement